High-risk defining events in follicular lymphoma following front line immunochemotherapy
Raul Cordoba, Chair of Community Stakeholder Committee at European Hematology Association (EHA) and Coordinator of the Lymphoma Unit and Associate Chief of Hematology Department at Jiménez Díaz Foundation, shared a recent article by Joshua W. D. Tobin on X:
“Hematology Outcomes for high-risk defining events in follicular lymphoma following front line immunochemotherapy in Blood Neoplasia at American Society of Hematology (ASH).”
Title: Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy
Authors: Joshua W. D. Tobin, Venkata A. Chikatamarla, Marko Matic, Alison Griffin, Rakin Chowdhury, Ross Salvaris, Amanda Goh, Harrison Black, Tsz Hung Tong, Callum Birks, Sanjiv Jain, Elizabeth Goodall, Shreerang Sirdesai, Thomas Trevis, Elizabeth Steinepreis, Yiyang Chen, Li Li, Glenn Broadby, Naadir Gutta, Kirk Morris, Tara Cochrane, Judith Trotman, Dipti Talaulikar, Jake Shortt, Georgina Hodges, Eliza A. Hawkes, Chan Y. Cheah, Allison Barraclough, Kate Manos, Anna Johnston, Jane Royle, Patrizia Mondello, Stephen M. Ansell and Greg Hapgood
Andrew M. Evens, Deputy Director for Clinical Services at Rutgers Cancer Institute, also reshared the recent article on X adding:
“We showed exactly this in a previous published randomized Phase 2 study of R-Bendamustine in high tumor burden follicular lymphoma.
C: OS among pts who experienced POD-24 (37/229, 16%).
D: OS for pts without transformation by POD-24 status (21/229).”
Authors: Andrew M. Evens, Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig, Andrew Quon, Erik A. Ranheim, Stephen M. Ansell, Puneet Singh Cheema, Philip A. Dy, Timothy E. O’Brien, Jane N. Winter, Terrence P. Cescon, Julie E. Chang and Brad S. Kahl
Raúl Córdoba Mascuñano, MD, PhD is a specialist in hematology and hemotherapy. He is the Chair of Community Stakeholder Committee at European Hematology Association (EHA) and Coordinator of the Lymphoma Unit and Associate Chief of Hematology Department at Jiménez Díaz Foundation. He is the principal investigator for numerous clinical trials for non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia and other chronic lymphoproliferative syndromes. He is a member of the ethical review board at his current workplace.
More posts featuring Raul Cordoba.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023